[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"plasma-cell-dyscrasias\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:plasma-cell-dyscrasias":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,72],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100164029","ohio-state-university-multiple-myeloma-and-amyloidosis-data-registry-and-sample-resource-100164029",false,"NCT01408225","Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource","Buckeye Surveillance, Contact, and Research for Multiple Myeloma and Amyloidosis","B-SCR-MM","Inclusion:\n\nDiagnosis of a plasma cell dyscrasia\n\nExclusion:\n\nPrisoners are excluded from participation as they have no standard access to the Ohio State myeloma clinic and would impede the research objective of this protocol.","ALL","18 Years",{"count":20,"type":21},5000,"ESTIMATED","10 Years","OBSERVATIONAL","The investigators are researching patients with diseases of their plasma cells in order to improve their quality and length of life. The investigators have created a database of patient information, blood samples, and bone marrow tissue in order to achieve the following three goals:\n\n* Surveillance: The investigators want to track what treatments patients get or don't get, how effective they are, how they feel, what complications they suffer, how long they stay in remission, and how long they live.\n* Contact: Because myeloma and amyloidosis are rare, less than 700 patients are diagnosed in the state of Ohio each year, patients often feel they don't have accurate information. The investigators want to provide them access to our clinical team (both phone and email consultations, even office visits for patients that can come to Columbus) as well as information regarding informational events pertaining to your disease and local support groups.\n* Research: Because nearly all myeloma and amyloid patients relapse and treatment is eventually unsuccessful, our focus is to develop more effective treatments that not only prolong life, but cure the disease. Periodically the investigators will inform them about clinical trials studying new drugs or treatment paradigms.",[26,27,28,29],"Plasma Cell Dyscrasias","Monoclonal Gammopathy of Undetermined Significance","AL Amyloidosis","Multiple Myeloma",[31,29,32],"MGUS","Tissue Bank","RECRUITING","2026-03-18",{"date":36,"type":37},"2026-03-23","ACTUAL",{"date":39,"type":37},"2011-03-17",{"date":41,"type":21},"2050-03",{"name":43,"class":44},"Ohio State University Comprehensive Cancer Center","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":58,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":4},"100621010","early-phase-1-safety-and-efficacy-of-gprc5d-car-t-cell-therapy-in-relapsedrefractory-plasma-cell-disorders-100621010","NCT07365059","Safety and Efficacy of GPRC5D CAR-T Cell Therapy in Relapsed\u002FRefractory Plasma Cell Disorders","Clinical Study on Safety and Efficacy of GPRC5D CAR-T Cell Therapy in Relapsed\u002FRefractory Plasma Cell Disorders","Inclusion Criteria:\n\nSubjects must meet all of the following criteria：\n\n* According to the World Health Organization (WHO) Classification of Haematopoietic and Lymphoid Tissue Tumours (2022), patients with relapsed\u002Frefractory plasma cell disorders that have received adequate treatment and lack effective therapeutic options, including: multiple myeloma, plasma cell leukemia, extramedullary plasmacytoma, solitary plasmacytoma, or primary amyloidosis.i) Relapsed: Disease progression occurs after one or more prior treatments, requiring salvage therapy, and does not meet the criteria for refractory disease.ii) Refractory: No response to initial treatment regimen or salvage therapy, or disease progression within 60 days after treatment. No response is defined as failure to achieve minimal response (MR) or disease progression during treatment.\n* The subject's predicted survival time is not less than three months.\n* Tumor cells confirmed to be GPRC5D positive by Flow Cytometry (FCM) or Immunohistochemistry.\n* The subject failed autologous and allogeneic hematopoietic stem cell transplantation.\n* Age 14-75 years (inclusive), both genders eligible.\n* ECOG performance status ≤ 2.\n* HGB≥70g\u002FL(transfusion permitted).\n* The functions of vital organs need to meet the following conditions: ①Creatinine ≤ 2.5 × ULN or Cockcroft-Gault creatinine clearance \\> 50 ml\u002Fmin (excluding decreased serum creatinine clearance due to lymphoma mass compression), Combination with hemodialysis treatment is permitted. ②LVEF≥50%,② Oxygen saturation ≥90%,③ SCr≤2.5ULN,④ALT and AST≤3ULN,TBil≤2ULN. In the investigator's judgment, if organ dysfunction is associated with the current disease, the enrollment decision will be made by the investigator.\n* Subjects intending to conceive must agree to use contraception prior to study enrollment and for six months post-study. In the event of pregnancy or suspected pregnancy, they should promptly notify the investigator.\n* The subject or guardian understands and signs the Informed Consent Form (ICF).\n\nExclusion Criteria:\n\nAny of the following conditions will not be eligible for enrolment:\n\n* Severe heart failure with left ventricular ejection fraction (LVEF) \\\u003C 50%.\n* History of severe pulmonary function impairment.\n* Concurrent other progressive malignant tumors.\n* Concurrent severe infection that cannot be effectively controlled.\n* Concurrent severe autoimmune disease or congenital immunodeficiency.\n* Active hepatitis (hepatitis B surface antigen (HBsAg) and\u002For hepatitis B core antibody (HBcAb) positive with HBV DNA copy number greater than the upper limit of normal at the study center; Anti-HCV positive with HCV-RNA copy number greater than the upper limit of normal at the study center).\n* Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS), or syphilis infection.\n* History of severe allergy to biological products (including antibiotics).\n* Received inactivated vaccines such as influenza vaccine, COVID-19 vaccine within 4 weeks prior to screening, or received live attenuated vaccines (such as measles, varicella vaccines) within 8 weeks.\n* Allogeneic hematopoietic stem cell transplant patients with persistent acute graft-versus-host disease (GVHD) one month after discontinuation of immunosuppressive agents.\n* Patients with other severe physical or mental illnesses or laboratory abnormalities that may increase the risk of study participation or interfere with study results, and patients considered unsuitable for this study by the investigator.","14 Years","75 Years",{"count":56,"type":21},18,"INTERVENTIONAL",[59],"EARLY_PHASE1","This study is an open-label, single-arm, dose-escalation and expansion, prospective clinical trial. It enrolls patients with relapsed\u002Frefractory plasma cell disorders, administers GPRC5D CAR-T cell therapy, follows up to observe adverse reactions after medication, collects relevant data on treatment efficacy, evaluates the safety and efficacy of CAR-T cells, and simultaneously investigates the cellular kinetic characteristics of CAR-T cells.",[26],"NOT_YET_RECRUITING","2026-01-15",{"date":65,"type":37},"2026-01-26",{"date":67,"type":21},"2026-01-25",{"date":69,"type":21},"2029-03-01",{"name":71,"class":44},"Qi deng",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":4,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":79,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":81,"conditions":82,"keywords":83,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":45},"100333068","the-indiana-myeloma-registry-100333068","NCT03616483","The Indiana Myeloma Registry","Collection of Specimens and Clinical Data to Create A Bio-repository for the Multiple Myeloma Program: The Indiana Myeloma Registry","Inclusion Criteria:\n\n1. Male or female patients ≥ 18 years of age at the time of informed consent\n2. Has been diagnosed with or is suspected to have one of the following:\n\n   1. Monoclonal Gammopathy of Undetermined Significance (MGUS)\n   2. Smoldering Multiple Myeloma\n   3. Multiple Myeloma\n   4. Bony or Soft Tissue Plasmacytoma\n   5. Primary Amyloidosis\n\nExclusion Criteria:\n\n\\\u003C 18 years of age\n\nHave not been diagnosed with one of the following:\n\nMonoclonal Gammopathy of Undetermined Significance (MGUS) b.Smoldering Multiple Myeloma c.Multiple Myeloma d.Bony or Soft Tissue Plasmacytoma e.Primary Amyloidosis",{"count":80,"type":21},2500,"This is a prospective, non-interventional, observational study. The purpose of this study is to collect data and bio-specimens that will support future research",[26],[84,85,86,87],"Multiple myeloma","Monoclonal gammopathy of undetermined significance","Plasmacytoma","Smoldering multiple myeloma","2025-11-06",{"date":90,"type":37},"2025-11-10",{"date":92,"type":37},"2018-06-18",{"date":94,"type":21},"2028-06-30",{"name":96,"class":44},"Indiana University"]